Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN NASDAQ:MYGN NASDAQ:SPPI NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.20-2.4%$1.35$1.09▼$4.50$765.62M0.577.04 million shs5.24 million shsMYGNMyriad Genetics$7.80-3.5%$7.00$3.76▼$23.74$725.71M1.971.14 million shs799,399 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$9.22-3.0%$9.04$2.54▼$11.24$567.40M0.891.76 million shs1.37 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron0.00%-8.40%-9.09%-2.44%-70.66%MYGNMyriad Genetics0.00%+4.00%+0.39%+75.28%-66.65%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem0.00%+7.58%+1.88%+80.78%+211.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.20-2.4%$1.35$1.09▼$4.50$765.62M0.577.04 million shs5.24 million shsMYGNMyriad Genetics$7.80-3.5%$7.00$3.76▼$23.74$725.71M1.971.14 million shs799,399 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVSTMVerastem$9.22-3.0%$9.04$2.54▼$11.24$567.40M0.891.76 million shs1.37 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron0.00%-8.40%-9.09%-2.44%-70.66%MYGNMyriad Genetics0.00%+4.00%+0.39%+75.28%-66.65%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem0.00%+7.58%+1.88%+80.78%+211.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.13Hold$3.79215.48% UpsideMYGNMyriad Genetics 2.13Hold$12.4559.67% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 2.80Moderate Buy$13.2944.10% UpsideCurrent Analyst Ratings BreakdownLatest SPPI, GERN, MYGN, and VSTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025VSTMVerastemCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight10/14/2025MYGNMyriad GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GERNGeronWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MYGNMyriad GeneticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.00(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$76.99M9.94N/AN/A$0.46 per share2.61MYGNMyriad Genetics$837.60M0.87$1.00 per share7.81$7.70 per share1.01SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VSTMVerastem$10K56,739.88N/AN/A($0.65) per share-14.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVSTMVerastem-$130.64M-$3.28N/AN/AN/AN/AN/A-119.85%11/5/2025 (Estimated)Latest SPPI, GERN, MYGN, and VSTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GERNGeron-$0.03N/AN/AN/A$55.24 millionN/A11/6/2025Q3 2025MYGNMyriad Genetics-$0.01N/AN/AN/A$205.26 millionN/A11/5/2025Q3 2025VSTMVerastem-$0.71N/AN/AN/AN/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.467.876.79MYGNMyriad GeneticsN/A1.421.28SPPISpectrum PharmaceuticalsN/A2.712.38VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%MYGNMyriad Genetics99.02%SPPISpectrum Pharmaceuticals21.67%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipGERNGeron7.42%MYGNMyriad Genetics2.10%SPPISpectrum Pharmaceuticals2.70%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70638.02 million590.68 millionOptionableMYGNMyriad Genetics2,70093.04 million91.09 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableSPPI, GERN, MYGN, and VSTM HeadlinesRecent News About These CompaniesVerastem, Inc. $VSTM is AIGH Capital Management LLC's 10th Largest Position3 hours ago | marketbeat.comVerastem FY2025 EPS Forecast Boosted by Cantor Fitzgerald4 hours ago | americanbankingnews.comVerastem FY2025 EPS Forecast Raised by Cantor Fitzgerald4 hours ago | marketbeat.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic ...October 19 at 6:20 AM | uk.finance.yahoo.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal AdenocarcinomaOctober 19 at 4:15 AM | businesswire.comVerastem (NASDAQ:VSTM) Earns Overweight Rating from Analysts at Cantor FitzgeraldOctober 19 at 2:59 AM | americanbankingnews.comVerastem assumed with an Overweight at Cantor FitzgeraldOctober 16, 2025 | msn.comVerastem (NASDAQ:VSTM) Receives Overweight Rating from Cantor FitzgeraldOctober 16, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Director Sells $75,496.98 in StockOctober 15, 2025 | marketbeat.comPaul Bunn Sells 8,333 Shares of Verastem (NASDAQ:VSTM) StockOctober 15, 2025 | insidertrades.comVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedOctober 14, 2025 | marketbeat.comVerastem's (VSTM) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comVerastem: Navigating Critical Steps In Commercialization And Development (Downgrade)October 7, 2025 | seekingalpha.comVerastem (NASDAQ:VSTM) Shares Up 4.9% - Still a Buy?October 7, 2025 | marketbeat.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Moderate Buy" by BrokeragesOctober 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average - Should You Sell?October 4, 2025 | marketbeat.comWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"September 21, 2025 | marketbeat.comVerastem (VSTM) Upgraded to Buy: Here's What You Should KnowSeptember 19, 2025 | zacks.comTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16, 2025 | finance.yahoo.comVerastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic OutlookSeptember 9, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, GERN, MYGN, and VSTM Company DescriptionsGeron NASDAQ:GERN$1.20 -0.03 (-2.44%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.25 +0.05 (+4.58%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Myriad Genetics NASDAQ:MYGN$7.80 -0.28 (-3.47%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$7.96 +0.17 (+2.12%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Verastem NASDAQ:VSTM$9.22 -0.29 (-3.05%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.54 +0.32 (+3.42%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
